ArticleJournal of thoracic disease2026
Analysis of clinicopathological characteristics in postoperative molecular residual disease-positive stage I non-small cell lung cancer patients.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple primary lung cancers (MPLCs) present unique clinical difficulties because of their genetically diverse independent tumors, requiring genetic testing to distinguish synchronous primaries from intrapulmonary metastases. While circulating tumor DNA (ctDNA) analysis shows potential for detecting molecular residual disease (MRD), tumor heterogeneity hinders its application. Thus, there is an urgent need to develop specific biomarkers and standardize liquid biopsy protocols to improve monitoring and treatment. The aim of this study was to analyze the clinicopathological characteristics of postoperative MRD-positive stage I non-small cell lung cancer (NSCLC) patients, with a focus on the potential utility of ctDNA in detecting MRD and guiding therapeutic decisions. Methods: Twelve patients with pulmonary nodules were analyzed. Paired tissue and plasma samples underwent genomic profiling via next-generation sequencing (NGS) using validated extraction/library preparation kits, following ethical standards. Rigorous quality controls were implemented to ensure sensitive variant detection. Results: Both solitary (n=5) and multiple nodules (n=7) carried Conclusions: Multifocal lung disease exhibits greater genomic complexity and enhanced ctDNA shedding, supporting its use as a disease-tracking tool. The findings identify actionable signatures for MRD surveillance and guide personalized therapeutic interventions based on observed clonal architectures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.